Cancer is a horrid disease that individuals fear. It swallows one whole and deteriorates a healthy immune system. Cancer alters ones metal and physical health making it difficult to defeat. Cancer is classified as the growth and spread of abnormal cells. It is the second most common cause of death in the U.S. and accounts for nearly 1 of every 4 deaths. There are many methods to treat cancer including chemotherapy, radiation, and targeted therapy. “Radiation therapy is one of the most efficient forms of cancer therapy.” (Menager, p. 2)The purpose of this paper is to summarizes the benefits and effectiveness of Pretargeted radioimmunotherapy (PRIT) and how it is more efficient at treating cancerous cells then Radioimmunotherapy (RIT) and Targeted…show more content… The results concluded, “PRIT was unambiguously superior to RIT with higher efficacy and lower or equivalent haematological toxicity.” (Rousseau, p. 1375)The study involved a mouse with LS174T human colorectal cancer. The injections were RIT & PRIT using the same antigen called CEA antibody. The maximum tumor uptake was lower with PRIT estimating 8.5% at 1 hour whereas RIT ranged at 33% at 2 days. The mouse injected with PRIT showed a lower blood absorbed dose. Tumor growth delay was superior at 150 days as compared to 53 days with RIT. This model concluded, “Longer term monitoring of treated animals and post-mortem examination of tumors showed that with PRIT 33% of the animals were cured, compared to none with RIT.” (Rousseau, p. 1374) Another similar study was performed in a mouse model of TT human medullary thyroid carcinoma and concluded tumor growth delay to be greater with PRIT. There was an “89% decrease in white blood cell count and a 66% decrease in platelet count compared with PRIT that had a 34% decrease in white blood count and a 39% decrease in platelet count.” Another similar study was conducted of 26 and 42 patients receiving Pretargeted radioimmunotherapy. They suffered with advanced Medullary thyroid carcinoma. 15 patients were receiving radioimmunotherapy using the anti-CEA MN-14 antibody. “Injected activities for RIT varied…show more content… RIT is composed of a monoclonal antibody called mAb. This antibody delivers radionuclides directly to the targeted cancerous cells. This treatment option delivers promising results and is successful at treating non-Hodgkin lymphoma. (Menager, p. 2) “RIT as consolidation enhances response rates and prolongs disease control.” (Witzig, p. 1194) “RIT with Y- ibritumomab tiuxetan or I-tositumomab combines a radiation-emitting radionuclide with an antibody targeting CD20 to treat B-cell non-Hodgkin lymphoma.” (Witzig, p. 1194). It is common and approved as a primary treatment for Follicular lymphoma. Findings have stated, “RIT produces longer durations of response.” (Witzig, p. 1197) An advantage of RIT includes a 1 weeks treatment on an outpatient basis. (Witzig, p. 1197) RIT involves the use of a monoclonal antibody to deliver radionucliotides directly to the targeted tumor
